Hans Edgar Bishop
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Transaction History
| SANA | ▲ Buy | Grant | 8,680 | $0 | 10/5/2026 | View on chart |
| SANA | ▲ Buy | Grant | 6,297 | $0 | 7/6/2026 | View on chart |
| SANA | ▲ Buy | Grant | 7,763 | $0 | 4/6/2026 | View on chart |
| SANA | ▲ Buy | Grant | 6,157 | $0 | 1/5/2026 | View on chart |
| SANA | ▲ Buy | Grant | 5,628 | $0 | 10/6/2025 | View on chart |
| SANA | ▲ Buy | Grant | 7,842 | $0 | 7/7/2025 | View on chart |
| SANA | ▲ Buy | Grant | 16,339 | $0 | 4/7/2025 | View on chart |
| SANA | ▲ Buy | Grant | 14,285 | $0 | 1/6/2025 | View on chart |
| SANA | ▲ Buy | Grant | 5,938 | $0 | 10/7/2024 | View on chart |
| SANA | ▲ Buy | Grant | 4,911 | $0 | 7/5/2024 | View on chart |
| SANA | ▲ Buy | Grant | 2,774 | $0 | 4/5/2024 | View on chart |
| A | ▲ Buy | Grant | 1,678 | $247K | 3/15/2024 | View on chart |
| A | ▲ Buy | Grant | 750 | $111K | 3/15/2024 | View on chart |
| SANA | ▲ Buy | Grant | 4,901 | $0 | 1/5/2024 | View on chart |
| SANA | ▲ Buy | Grant | 6,925 | $0 | 10/5/2023 | View on chart |
| SANA | ▲ Buy | Grant | 4,152 | $0 | 7/5/2023 | View on chart |
| SANA | ▲ Buy | Grant | 7,716 | $0 | 4/5/2023 | View on chart |
| A | ▲ Buy | Grant | 741 | $101K | 3/16/2023 | View on chart |
| A | ▲ Buy | Grant | 1,658 | $227K | 3/16/2023 | View on chart |
| SANA | ▲ Buy | Grant | 6,702 | $0 | 1/5/2023 | View on chart |
| SANA | ▲ Buy | Grant | 4,012 | $0 | 10/5/2022 | View on chart |
| LYEL | ▲ Buy | Option Exercise | 145,380 | $15K | 9/8/2022 | View on chart |
| SANA | ▲ Buy | Grant | 3,328 | $0 | 7/5/2022 | View on chart |
| SANA | ▲ Buy | Grant | 2,880 | $0 | 4/5/2022 | View on chart |
| A | ▲ Buy | Grant | 797 | $109K | 3/17/2022 | View on chart |
| A | ▲ Buy | Grant | 1,785 | $244K | 3/17/2022 | View on chart |
| LYEL | ▲ Buy | Option Exercise | 993,428 | $99K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Sana Biotechnology Featured in Diabetes Treatment Analysis
Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.
Sana Biotechnology Featured in Diabetes Treatment Analysis. Sana Biotechnology was the subject of a recent analysis titled 'A Shot At Diabetes,' which likely examines the company's potential in treating the condition. This coverage places the stock in the spotlight for investors watching biotech developments. The stock is currently trading near its support level, with an RSI indicating it may be oversold.